Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.

ABSTRACT:

Background

Endometrial cancer (EC) therapeutic and diagnostic approaches have been changed by the development of a new prognostic molecular classification, the introduction of dostarlimab in microsatellite instability (MSI) high pre-treated advanced EC patients with further expected innovation deriving from lenvatinib plus pembrolizumab regardless MSI status. How this is and will be translated and embedded in the clinical setting in Italy is not known; this is why we developed Multicentre Italian Trials in Ovarian cancer and gynaecologic malignancies (MITO) survey on the current practice and expected future changes in EC.

Methods

We designed a self-administered, multiple-choice online questionnaire available only for MITO members for one month, starting in April 2021.

Res

SUBMITTER: Giannone G 

PROVIDER: S-EPMC9185800 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature